1. Home
  2. ARWR vs RGEN Comparison

ARWR vs RGEN Comparison

Compare ARWR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arrowhead Pharmaceuticals Inc.

ARWR

Arrowhead Pharmaceuticals Inc.

HOLD

Current Price

$67.01

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$164.34

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARWR
RGEN
Founded
2003
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
8.2B
IPO Year
1993
N/A

Fundamental Metrics

Financial Performance
Metric
ARWR
RGEN
Price
$67.01
$164.34
Analyst Decision
Strong Buy
Buy
Analyst Count
10
10
Target Price
$63.70
$174.90
AVG Volume (30 Days)
2.4M
566.0K
Earning Date
02-09-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
$829,448,000.00
$707,890,000.00
Revenue This Year
N/A
$17.84
Revenue Next Year
N/A
$12.44
P/E Ratio
N/A
$5,307.14
Revenue Growth
23258.15
11.74
52 Week Low
$9.57
$102.97
52 Week High
$72.36
$182.52

Technical Indicators

Market Signals
Indicator
ARWR
RGEN
Relative Strength Index (RSI) 60.22 53.89
Support Level $65.94 $161.41
Resistance Level $69.71 $167.65
Average True Range (ATR) 3.16 4.48
MACD -1.04 0.01
Stochastic Oscillator 56.15 68.63

Price Performance

Historical Comparison
ARWR
RGEN

About ARWR Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: